Johnson & Johnson subsidiary Janssen Biotech Inc. wants a court to block a generic copy of blockbuster oncology drug Imbruvica until 2033.
Imbruvica-maker Janssen and AbbVie’s Pharmacylics LLC are suing Hetero USA Inc. for infringement over its bid to make and sell a generic version of the myeloma drug. They’re seeking to block Food and Drug Administration approval for the generic until after the last of five patents covering the drug expires in August 2033.
Protecting the oncology franchise is key for the companies especially because worldwide Imbruvica sales hit $2.57 billion in 2017, an Increase of 40.5 percent from ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.